Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations

Int J Tuberc Lung Dis. 2015 Oct;19(10):1227-9. doi: 10.5588/ijtld.14.0277.

Abstract

The purpose of the present study was to correlate gyrA mutations found in Mycobacterium tuberculosis isolates using the GenoType(®) MTBDRsl assay with minimum inhibitory concentrations of the fluoroquinolone levofloxacin (LVX). Of 123 archived clinical M. tuberculosis isolates evaluated, 93 isolates had an Ala90Val, Ser91Pro, Asp94Ala, Asn/Tyr, Gly or His mutation and 30 were wild-type. Phenotypically, gyrA mutations Ala90Val, Ser91Pro or Asp94Ala showed a low level of resistance to LVX, while Asp94Asn/Tyr, Asp94Gly or Asp94His mutations had high-level resistance.

MeSH terms

  • Antitubercular Agents / pharmacology*
  • DNA Gyrase / genetics
  • Drug Resistance, Bacterial
  • Humans
  • Levofloxacin / pharmacology*
  • Microbial Sensitivity Tests
  • Mutation
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / isolation & purification
  • Tuberculosis / drug therapy
  • Tuberculosis / microbiology

Substances

  • Antitubercular Agents
  • Levofloxacin
  • DNA Gyrase